(The Chupei Biomedical Plant of Creative Media Products (CMP) is officially inaugurated; esteemed guests from industry, government, and academia gather for a group photo.)
Chi-Sen Biotech Officially Opens Asia’s First Regenerative Medicine PIC/S GMP Cell Culture Medium Manufacturing Base
With the rapid growth of the regenerative medicine and cell therapy industries, the importance of key raw materials and testing services is increasingly prominent. Chi-Sen Biotech, with over 45 years of experience in the biotechnology industry, has invested NT$500 million to build a new factory of over 650 ping (approximately 166 square meters) in the Hsinchu Biomedical Park. On March 18th, the “Opening Ceremony of the New Factory in Hsinchu Biomedical Park” was held, officially launching the cell culture medium manufacturing base designed to meet international PIC/S GMP standards. The facility also incorporates a process platform centered on a pharmaceutical-grade isolator system, signifying Chi-Sen Biotech’s strengthened position in the regenerative medicine industry supply chain.
Cell culture medium is considered a “hidden key” in cell therapy. Its quality and stability directly affect cell culture efficiency and the safety of the final product. As regenerative medicine regulations in various countries gradually improve, the specifications of cell culture medium are also gradually increasing. Major international suppliers have begun to provide products with PIC/S GMP standards. Therefore, suppliers with international standard manufacturing capabilities will play an increasingly important role in industry development. Meanwhile, under the government’s active promotion of the National Drug Resilience Development Plan, strengthening biomedical manufacturing capabilities and the resilience of key material supply chains has become an important direction for industry development.
Tsai Yueh-ting, General Manager of Chi-Sheng Biotech, pointed out that with the accelerated development of cell and gene therapy products, quality control and traceability of cell culture media and related reagents in the manufacturing process are becoming increasingly critical. The newly opened Zhubei biomedical plant is a response to the industry’s demand for high-quality key materials, aligning with government policies and echoing the localization and supply chain self-sufficiency of Taiwan’s biomedical industry. In the future, the plant will further expand its production capacity and collaborate with international partners to expand into the Southeast Asian market, propelling Taiwan’s biomedical industry onto the international stage.
(Distinguished guests toured the factory area under a guided tour, observing the manufacturing equipment and factory layout up close.)
At the opening ceremony, Director Hu Shih-min of the Hsinchu Science Park Administration, along with guests from industry, government, and academia including Po-Rei Pharmaceutical, Medtronic Technology, Esco, the Chinese Association of Aseptic Preparations, and National Yang-Ming University, participated in the event. Chi-Shin Biotech led the guests on a site visit, providing an in-depth understanding of the new factory’s positioning and application within the regenerative medicine manufacturing system. They also further discussed the development trends and cooperation opportunities in the regenerative medicine industry.
Chi-Shin Group has long been deeply involved in microbial testing and biomedical inspection services. Tsai Yueh-ting stated that in the future, Chi-Shin will combine its cell culture medium manufacturing and testing service capabilities to provide integrated support from key raw materials to quality verification. As regenerative medicine gradually moves towards industrialization, the completion of Chi-Shin Biotech’s new factory in the Hsinchu Biomedical Park not only symbolizes a significant milestone in the company’s regenerative medicine manufacturing strategy but also adds crucial energy to Taiwan’s biomedical industry supply chain.